BME:PHMBiotechs
Surging Zepzelca Royalties and Profitability Could Be A Game Changer For Pharma Mar (BME:PHM)
Pharma Mar recently reported a sharp improvement in profitability, with EBITDA reaching €25.1 million, as high‑margin license payments and rapidly growing global royalties from its cancer drug Zepzelca, including in the US and China, boosted results.
Beyond the headline earnings turnaround, the breadth of Zepzelca uptake across major markets underscores how royalty‑driven income is becoming a more central earnings pillar for Pharma Mar.
We’ll now examine how the stronger high‑margin royalty...